The trouble started in mid-October. That's when the price of Amgen Inc.'s shares, which had been at about $67, fell like autumn leaves, dipping just below $62 before an upsurge became evident in the first part of last week.

Though still waiting for an action letter from the FDA, CV Therapeutics Inc.'s news Thursday that an advisory panel has slated for Dec. 9 a review of Ranexa (ranolazine) for chronic angina was enough to boost the company's stock. (BioWorld Today)